The document discusses pharmaceutical companies' use of social media and mobile applications. It notes milestones and mistakes in pharma's adoption of these technologies. It also summarizes guidelines from regulatory agencies on topics like adverse event reporting, off-label promotion, and editing drug information online. Survey results show most agree self-regulation is needed for mobile medical apps. The document provides resources for assessing social media readiness and best practices in mobile health.
Pharma Marketing Blog 2010: The Year in ImagesPharma Guy
Images from Pharma Marketing Blog chosen by the "real" Pharmaguy to represent the major issues of pharmaceutical marketing in 2010. Includes notations and links to blog posts.
Overcoming Pharma’s Social Media & Mobile Challenges Pharma Guy
This is a presentation I made at a Bayer HealthCare Grants4Apps™ meeting on June 11, 2013, in Berlin. It highlights some pharma social media and mobile app “milestones” or “firsts” that have paved the way for others to follow.
I identify the “Pioneers” who have helped the industry navigate through “uncharted” territory lacking regulatory guidance.
I also analyze some “mistakes” made by both leaders and followers. Only those who learn from thee mistakes of their competitors will move forward. Those who learn from their OWN mistakes will move forward fastest!
Finally, I present some ideas for “best practices” and “guiding principles” that may help you avoid regulatory actions.
In recent years the use of Twitter during ASCO’s annual meeting of Oncologists has become a central theme at the event. Two members of our Digital Strategy team, Steve Hunt and Jason Mazur, explored the #ASCO15 hashtag and how Pharmaceutical companies utilised the channel during this year’s event.
Specially, the research addresses:
- Which pharma companies had the most ‘influence’
- The tweet strategies they deployed to achieve this influence
- Some of our favourite pharma tweets
- Thoughts for #ASCO16
For more information please contact Steve Hunt on steven.hunt@ashfieldhealthcare.com or visit www.ashfieldhealthcare.com.
Who are the pharma social media butterflies?Ogilvy Health
Who is doing the most proactive social media engagement within the pharmaceutical industry? Should pharma really compare itself to other sectors when it comes to social media? Is pharma’s use of social media evolving in the right direction? What are the defining characteristics of those pharma companies who are engaging more?
These are just some of the questions we keep hearing when it comes to pharma and social media. So we thought a bit of analysis of the industry would be interesting to see who was driving the party and who was standing back to watch and learn – the social butterflies and wallflowers.
Patients Rising: How to Reach Empowered, Digital Health Consumerse-Patient Connections
Kru Research's white paper discussing how to reach out to empowered, digital, health consumers or e-Patients. Discussion of participatory medicine, digital health consumers, e-Patients, web 2.0, the power of social media, ROI of social media, regulatory concerns, HIPAA, FDA, adverse event reporting, and the future of social media in health marketing.
Pharma Marketing Blog 2010: The Year in ImagesPharma Guy
Images from Pharma Marketing Blog chosen by the "real" Pharmaguy to represent the major issues of pharmaceutical marketing in 2010. Includes notations and links to blog posts.
Overcoming Pharma’s Social Media & Mobile Challenges Pharma Guy
This is a presentation I made at a Bayer HealthCare Grants4Apps™ meeting on June 11, 2013, in Berlin. It highlights some pharma social media and mobile app “milestones” or “firsts” that have paved the way for others to follow.
I identify the “Pioneers” who have helped the industry navigate through “uncharted” territory lacking regulatory guidance.
I also analyze some “mistakes” made by both leaders and followers. Only those who learn from thee mistakes of their competitors will move forward. Those who learn from their OWN mistakes will move forward fastest!
Finally, I present some ideas for “best practices” and “guiding principles” that may help you avoid regulatory actions.
In recent years the use of Twitter during ASCO’s annual meeting of Oncologists has become a central theme at the event. Two members of our Digital Strategy team, Steve Hunt and Jason Mazur, explored the #ASCO15 hashtag and how Pharmaceutical companies utilised the channel during this year’s event.
Specially, the research addresses:
- Which pharma companies had the most ‘influence’
- The tweet strategies they deployed to achieve this influence
- Some of our favourite pharma tweets
- Thoughts for #ASCO16
For more information please contact Steve Hunt on steven.hunt@ashfieldhealthcare.com or visit www.ashfieldhealthcare.com.
Who are the pharma social media butterflies?Ogilvy Health
Who is doing the most proactive social media engagement within the pharmaceutical industry? Should pharma really compare itself to other sectors when it comes to social media? Is pharma’s use of social media evolving in the right direction? What are the defining characteristics of those pharma companies who are engaging more?
These are just some of the questions we keep hearing when it comes to pharma and social media. So we thought a bit of analysis of the industry would be interesting to see who was driving the party and who was standing back to watch and learn – the social butterflies and wallflowers.
Patients Rising: How to Reach Empowered, Digital Health Consumerse-Patient Connections
Kru Research's white paper discussing how to reach out to empowered, digital, health consumers or e-Patients. Discussion of participatory medicine, digital health consumers, e-Patients, web 2.0, the power of social media, ROI of social media, regulatory concerns, HIPAA, FDA, adverse event reporting, and the future of social media in health marketing.
Overcoming Pharma’s Social Media Challenges Pharma Guy
I this presentation, I present pharma social media “milestones” or “firsts” that have paved the way for others to follow and identify the “Pioneers” who have helped the industry navigate through “uncharted” territory lacking regulatory guidance.
I also review some “mistakes” made by both leaders and followers. Only those who learn from the mistakes of their competitors will move forward. Those who learn from their OWN mistakes will move forward fastest!
Finally, I offer some ideas for “best practices” and “guiding principles” that may help pharma avoid regulatory actions.
Retailer Therapy - Campaign for Safe Cosmetics: Ranking Retailers on their Co...v2zq
Retailer Therapy - Campaign for Safe Cosmetics: Ranking Retailers on their Commitment to Personal Care Product & Cosmetics Safety - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto Ecológico, Tecnologías Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~
Managing knowledge and relationship by web to improve sales efficacy - SFE Su...USP e Plexus
Presentation exploring how pharma industry in Brazil and around world are using the web 2.0 to establish interactions with medical community (social networking, twitter, facebook, youtube, linkedin, etc)
Mobile Trends in Pharma & Healthcare Advertising | Silverlight Digital lorigo
Seventy percent of Internet use is now on mobile — and taking market share from other platforms. Adapted from a live presentation from Google NY’s Mobile Trends in Pharma & Healthcare Advertising Event, Silverlight Digital explores key trends that pharma and healthcare advertisers must take advantage of to increase performance in today's marketplace.
Discusses tools and tips for implementing innovative services with free social media tools and mobile apps applied in libraries and other working environments. Iincludes apps supporting the latest trends in cloud storage, crowdfunding, ebooks, makerspaces, MOOCs, news aggregation, photo and video sharing, self-publishing, social networking and bookmarking, video conferencing, visualization and wearable technology --all tailored to the needs of libraries and the communities they serve.
How to Create, Equip & Manage an Event Tech, Mobile & Social Media Toolbox I...Echelon Design
Social media and mobile technologies offer new opportunities, but many think these tools are reserved for organizations with larger budgets and resources. For the constrained event professional, it can be a challenge to incorporate new approaches into your programs. Join us for an interactive and hands-on workshop where you’ll learn how to:
• Convert “blue sky” ideas into reality
• Tackle difficult goals with easy and low cost implementation
• Experiment with new approaches to gauge audience responsiveness and effectiveness
• Structure technology to increase traffic, optimize leads, and improve quality of engagement
Mobile strategy for community news and engagementAmy Gahran
Amy Gahran's presentation on how local or regional news and info projects can use mobile technology to engage communities: where to start, what to focus on. For the Knight Community Info Challenge bootcamp, Sept. 24, 2012.
Social Media & Mobile: How the Last 5 Years Have Forever Changed High-Tech B2...Scott Salkin
This presentation by Scott Salkin, CEO and Founder of IDS Technology Marketing, explores the rapid growth of social media and mobile marketing over the last five years, and it's dramatic impact on the business-to-business (b2b) sales and marketing pipeline. See how social media and mobile has impacted everything from B2B lead generation and nurturing to sales enablement and training. And check-out some amazing stats on the proven impact social media and mobile can have on your bottom-line revenue.
How Qatar uses WhatsApp, Snapchat and other social mediaMOTC Qatar
Insights from a new study into how people in Qatar use social media. Produced by ictQATAR's Rassed team the research looks not just what social media people in Qatar use, but also how and why they use it.
Produced in partnership with Ipsos Qatar, the study features conclusions from interviews conducted with 1,000 residents (500 Qataris and 500 non-Qataris) during September-October 2014.
Covering eight different social media services - ranging from older more established networks like Facebook, Instagram and Twitter to newer entrants like Snapchat, WhatsApp and Path – the study provides unique insights into how Qatar uses social media at the end of 2014.
These slides provide an overview of a white paper - “Connecting with Patients, Overcoming Uncertainty” white paper was produced by Envision Solutions, TNS Media Intelligence/Cymfony and law firm Seyfarth Shaw.
mHealth and Digital Masters : Novartis Vs KodakJoseph Pategou
During years, pharma companies have been trying to bring more value to patients and physicians by using mHealth.
In this study we observed the consequences of a slow transition to digital on a leader in his sector (Novartis Vs Kodak). We also think that pharma companies need to move from mHealth to Digital Masters to bring the best value to all stakeholders.
Some facts:
Digital Masters outperform their peers*
-26% more profitable than their average industry competitors
-9% percent more revenue with their existing physical capacity
-More efficiency in their existing products and processes
-More Productivity
(*): LEADING DIGITAL: Turning technology into business transformation, Havard Business Review press
Social Media and Health Care: A Global PerspectiveSpectrum
On January 27, 2010, Spectrum and Aurora presented a PRSA webinar on how to leverage social media in a regulated industry.
It is important for the health care industry to begin 2010 with a clear vision for embracing social media. In 2009, health care regulators finally started to address the issue - from the FDA's public hearings to the creation of a digital marketing working group by the UK's Pharmaceutical Marketing Society. There is no denying that consumers are constantly turning to the Internet as a source for health information. As communications professionals, we need to understand the opportunities, challenges and threats of the emerging digital world.
Overcoming Pharma’s Social Media Challenges Pharma Guy
I this presentation, I present pharma social media “milestones” or “firsts” that have paved the way for others to follow and identify the “Pioneers” who have helped the industry navigate through “uncharted” territory lacking regulatory guidance.
I also review some “mistakes” made by both leaders and followers. Only those who learn from the mistakes of their competitors will move forward. Those who learn from their OWN mistakes will move forward fastest!
Finally, I offer some ideas for “best practices” and “guiding principles” that may help pharma avoid regulatory actions.
Retailer Therapy - Campaign for Safe Cosmetics: Ranking Retailers on their Co...v2zq
Retailer Therapy - Campaign for Safe Cosmetics: Ranking Retailers on their Commitment to Personal Care Product & Cosmetics Safety - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto Ecológico, Tecnologías Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~
Managing knowledge and relationship by web to improve sales efficacy - SFE Su...USP e Plexus
Presentation exploring how pharma industry in Brazil and around world are using the web 2.0 to establish interactions with medical community (social networking, twitter, facebook, youtube, linkedin, etc)
Mobile Trends in Pharma & Healthcare Advertising | Silverlight Digital lorigo
Seventy percent of Internet use is now on mobile — and taking market share from other platforms. Adapted from a live presentation from Google NY’s Mobile Trends in Pharma & Healthcare Advertising Event, Silverlight Digital explores key trends that pharma and healthcare advertisers must take advantage of to increase performance in today's marketplace.
Discusses tools and tips for implementing innovative services with free social media tools and mobile apps applied in libraries and other working environments. Iincludes apps supporting the latest trends in cloud storage, crowdfunding, ebooks, makerspaces, MOOCs, news aggregation, photo and video sharing, self-publishing, social networking and bookmarking, video conferencing, visualization and wearable technology --all tailored to the needs of libraries and the communities they serve.
How to Create, Equip & Manage an Event Tech, Mobile & Social Media Toolbox I...Echelon Design
Social media and mobile technologies offer new opportunities, but many think these tools are reserved for organizations with larger budgets and resources. For the constrained event professional, it can be a challenge to incorporate new approaches into your programs. Join us for an interactive and hands-on workshop where you’ll learn how to:
• Convert “blue sky” ideas into reality
• Tackle difficult goals with easy and low cost implementation
• Experiment with new approaches to gauge audience responsiveness and effectiveness
• Structure technology to increase traffic, optimize leads, and improve quality of engagement
Mobile strategy for community news and engagementAmy Gahran
Amy Gahran's presentation on how local or regional news and info projects can use mobile technology to engage communities: where to start, what to focus on. For the Knight Community Info Challenge bootcamp, Sept. 24, 2012.
Social Media & Mobile: How the Last 5 Years Have Forever Changed High-Tech B2...Scott Salkin
This presentation by Scott Salkin, CEO and Founder of IDS Technology Marketing, explores the rapid growth of social media and mobile marketing over the last five years, and it's dramatic impact on the business-to-business (b2b) sales and marketing pipeline. See how social media and mobile has impacted everything from B2B lead generation and nurturing to sales enablement and training. And check-out some amazing stats on the proven impact social media and mobile can have on your bottom-line revenue.
How Qatar uses WhatsApp, Snapchat and other social mediaMOTC Qatar
Insights from a new study into how people in Qatar use social media. Produced by ictQATAR's Rassed team the research looks not just what social media people in Qatar use, but also how and why they use it.
Produced in partnership with Ipsos Qatar, the study features conclusions from interviews conducted with 1,000 residents (500 Qataris and 500 non-Qataris) during September-October 2014.
Covering eight different social media services - ranging from older more established networks like Facebook, Instagram and Twitter to newer entrants like Snapchat, WhatsApp and Path – the study provides unique insights into how Qatar uses social media at the end of 2014.
These slides provide an overview of a white paper - “Connecting with Patients, Overcoming Uncertainty” white paper was produced by Envision Solutions, TNS Media Intelligence/Cymfony and law firm Seyfarth Shaw.
mHealth and Digital Masters : Novartis Vs KodakJoseph Pategou
During years, pharma companies have been trying to bring more value to patients and physicians by using mHealth.
In this study we observed the consequences of a slow transition to digital on a leader in his sector (Novartis Vs Kodak). We also think that pharma companies need to move from mHealth to Digital Masters to bring the best value to all stakeholders.
Some facts:
Digital Masters outperform their peers*
-26% more profitable than their average industry competitors
-9% percent more revenue with their existing physical capacity
-More efficiency in their existing products and processes
-More Productivity
(*): LEADING DIGITAL: Turning technology into business transformation, Havard Business Review press
Social Media and Health Care: A Global PerspectiveSpectrum
On January 27, 2010, Spectrum and Aurora presented a PRSA webinar on how to leverage social media in a regulated industry.
It is important for the health care industry to begin 2010 with a clear vision for embracing social media. In 2009, health care regulators finally started to address the issue - from the FDA's public hearings to the creation of a digital marketing working group by the UK's Pharmaceutical Marketing Society. There is no denying that consumers are constantly turning to the Internet as a source for health information. As communications professionals, we need to understand the opportunities, challenges and threats of the emerging digital world.
Social Media Guidelines and Safeguards for the Phamaceutical Industry: What Y...Stacy Lukasavitz Steele
This is a POV I wrote in June 2010 advising pharmaceutical companies on what they should do in the social media space until the FDA issues its official guidelines. It will soon be updated.
Skills interpreting data, understanding policy responses, communicating to th...MeTApresents
'Skills – interpreting data, understanding policy responses, communicating to the public/patient', presentation by Kweku Rockson and Alex Dodoo during MeTA Ghana, CSO & media orientation workshop, 16 April 2009.
The Impact and Use of Social Media in PharmacovigilanceCovance
This white paper examines how the influence and reach of the internet and social media can be harnessed to drive valuable outcomes for the PV industry. In this paper, we look at available regulatory guidelines, current state and future considerations for use of social media in PV, possible areas of influence, expected challenges, potential solutions and next steps.
Life science companies need to ensure their business initiatives take advantage of social media analytics. Read about the challenge of maximizing the opportunity and generating value from real world patient insights.
The thoughts of patients, health advocates, former government officials, bloggers and others who participated in a roundtable discussion that AstraZeneca convened in 2010.
Navigating FDA’s Social Media Guidelines for Medical Devices.pdfdnyaneshwarivedpatha1
Ensuring Regulatory Compliance and Monitoring in Medical Device Marketing
Compliance and Monitoring
FDA’s Stance on Continued Monitoring of Third-Party Websites and Social Media Platforms
The FDA emphasizes the importance of continued monitoring of third-party websites and social media platforms by medical device companies. This monitoring helps ensure that information related to their products remains accurate, up-to-date, and compliant with regulatory guidelines. Companies are responsible for actively monitoring user-generated content and addressing any misleading or inaccurate information promptly.
Non-Objection to Voluntary Corrections Meeting FDA’s Recommendations
The FDA encourages voluntary corrections by medical device companies to address misinformation or inaccuracies in their marketing materials. When companies take proactive steps to correct such information in line with FDA’s recommendations, the agency generally does not object to these corrective actions. This reflects a collaborative approach between regulatory authorities and industry stakeholders to uphold transparency and accuracy in marketing communications.
Reminder for Companies to Comply with Applicable Regulatory Requirements in Corrective Actions
Medical device companies must ensure that their corrective actions comply with all applicable regulatory requirements set forth by the FDA. This includes providing truthful and non-misleading information, adhering to labeling guidelines, and disclosing affiliations or relationships related to corrective information. Compliance with these requirements is essential to maintain ethical standards and regulatory compliance in marketing practices.
Recommendation for Companies to Maintain Records for Potential FDA Inquiries
As part of regulatory compliance, companies are advised to maintain detailed records of their marketing activities, corrective actions, and communications related to their medical devices. These records serve as evidence of compliance with FDA guidelines and can be valuable in addressing potential inquiries or audits by the FDA. Proper record-keeping demonstrates transparency, accountability, and a commitment to regulatory compliance within the medical device industry.
By adhering to these compliance and monitoring practices, medical device companies can uphold regulatory standards, address misinformation effectively, and maintain trust and credibility among consumers and regulatory authorities alike.
Navigating FDA Guidelines: Best Practices for Medical Device Advertising
Conclusion and Recommendations
Recap of Key Points from FDA’s Proposed Guidelines and Relevant Regulations
Throughout this discussion, we’ve explored the FDA’s proposed guidelines and regulations concerning medical device advertising on social media platforms. Key points include the importance of accurate and balanced communication of benefits and risks, addressing misinformation, and complying with FDA requirements for promotional
Empowering patients and health professionals through digital contentVanksen
From the innovations developed by international laboratories (use of AI and machine learning, biopharma, digital health…) to the latest international reforms designed to widen the access to care, all arrows point to the same direction: health has become an increasingly important topic, and even more so since the pandemic.
Vanksen’s experts zoomed in to try and understand the ways in which digital levers can empower pharma players around the world.
Experience taught us that marketing and communication have different rules if you are the CDO or CMO of a European lab. It is strictly forbidden to target patient audiences with content advertising subscription medication. So, what can they do?
https://www.vanksen.com/en/insights/empowering-patients-health-professionals-through-digital-content
지난 2013년 6월 “Digital Health: Building Social Confidence in Pharma’라는 제목으로 웨버 샌드윅(Weber Shandwick)이 발표한 리포트는 현재 글로벌 제약회사에서 소셜 미디어 커뮤니케이션 활동을 책임지는 13명의 임원들과 마케팅 컨설턴트가 참여했으며, 제약회사들의 소셜 미디어 도입 현황, 도입 시 혜택, 극복과제, 실행 방안 등 주제별 주요 인사이트가 반영되어 있다.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
I’ll start with social media and the difficult road the drug industry has traveled in its attempt to master social media and integrate it into its marketing communications strategy. FDA’s famous 14 letters alerted pharma to the fact that the agency is now looking carefully at how the industry promotes its products via the Internet. I pushed this issue in December 2006 when I blogged that “FDA should be taking a closer look at drug promotion via the Internet.” And the timing of my 2009 April Fools’ joke was perfect – many pharma people were primed to believe the FDA actually came out with digital guidance and several were angry at me for playing such a cruel joke!
I’d like to believe that my call for public hearings back in April 2009, motivated the FDA to act. Unfortunately, however, the hearings were hastily organized and as a result, they did not include ALL stakeholders as I urged. Consumer advocates were missing and agencies and industry service providers dominated the speaker roster. Relative to the 1996 hearing, few pharma companies made presentations at the 2009 hearing.This shirt appeared in my presentation to the FDA at the November hearings! It was my way of predicting the outcome.
Congress put some language in recent legislation that requires the FDA to issue social media guidance by July 2014. Does that mean the FDA will deliver? If not, it wouldn't be the first time that a government agency missed deadlines imposed by Congress.I call this FDA's "Social Media Guidance Cliff.”FDA’s (FDASIA)-TRACK must include the deliverables with statutory dates, as well as other tasks required to implement the FDA Safety and Innovation Act.To date, no completed tasks for SM guidance have been entered in the database, which indicates to me that the FDA will not soon deliver any draft guidance but will wait until the very last minute.Why the delay? For one thing, the industry is pushing for legally binding regulations, not guidance and threatening a First Amendment challenge to any guidance drafted by the FDA. Pfizer, for example, said in comments to the FDA that the proposed social media guidance “raises First Amendment concerns.” Guidance, said Pfizer, is too vague and engenders “extensive [First Amendment] litigation.”
FDA had questions about pharma correcting misinformation about drugs on third-party sites. One important 3rd-party site where misinformation about drugs may be found is Wikipedia.“If you want your customers to access information about your products from the quality perspective and in the simplest way, you have to deal with using Wikipedia,” said Dr. Bertalan Meskó (@Berci).Berci, however, did not mean that pharma companies should secretly and selectively alter information as in this example: In July of 2007, employees of Abbott Laboratories altered entries to Wikipedia to eliminate information about a Mayo Clinic study that revealed that patients taking the arthritis drug Humira faced triple the risk of developing certain kinds of cancers and twice the risk of developing serious infections.
Another one of my surveys specifically asked respondents under what circumstances should pharma edit drug articles on Wikipedia. The best practice is to appoint an “official” Wikipedia editor as recommended by Berciand ensure that editors reveal ties to companies. Although a substantial minority of respondents feel that FDA should regulate pharma edits to Wikipedia drug articles, in comments submitted to the FDA docket, PhRMA suggested that manufacturers would welcome correcting misinformation about their products posted to 3rd-party sites such as Wikipedia IF these corrections were NOT subject to FDA regulation.
Over the 2011 Christmas holidays, while most of us were still on vacation, the FDA quietly issued without fanfare "Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices." Section VI. of this guidance addresses responding to unsolicited requests on public forums such as the Internet. While this may not be the "social media" guidance many people were expecting, it does include guidelines for responding to unsolicited requests for off-label information encountered through "emerging electronic media.”The primary take-away is that such requests NOT be handled by sales or marketing people and that responses should be via private channels not via open forums such as on Youtube, blogs, and Twitter.
Despite the lack of FDA guidance, pharmaceutical marketers have come a long way in integrating social media into their overall marketing strategy.These are data from the Social Media Readiness survey tool I have been running since December, 2007. Over 300 marketers working for drug or device companies have taken the survey. The survey asks questions to evaluate readiness in three categories: regulatory (e.g., aversion of risk), culture (e.g., sensitivity to criticism), and personal experience. Scores are calculated. This compares scores prior to July, 2009, with scores afterward.Not every pharma company, however, is at the same point in the adoption curve. Some are more willing to take "risks," some are more savvy about applicable FDA regulations, and some are more knowledgeable about social media in general.
Let’s look at more detail regarding how pharma employees rate their companies’ readiness to deal with social media readiness issues.You can see that in the early period prior to July 2009, the majority of respondents thought their companies had a “very cautious” regulatory climate with only 24% saying the climate was “very aggressive.” Theses days, it seems from these results, pharma companies are seen as much less cautious and more aggressive.I guess that is due to the lack of significant FDA “warning” letters being sent that involve social media. In other words, the “received wisdom” is that pharma companies are negotiating the social media regulatory challenges without specific guidance from the FDA.Be careful though! The FDA hammer may fall again just as it did the day after April Fools’ Day in 2009.
Of course, there is good reason why pharma companies fear comments on Facebook as this case demonstrates.However, this could have been prevented:Problem #1: No one at S-A was monitoring this site or seemed to be responsible for it.Problem #2: There was no policy in place for what constitutes acceptable comments and how comments would be moderated or deleted.Problem #3: There was no social media “crisis management plan” other than “remove all comments!”
Sanofi learned from its mistakes and even spoke about them in a public forum; i.e., my Pharma Marketing Talk show titled: “What Sanofi-Aventis Learned from Its FaceBook Experience & What the Experts Recommend It Do Now.” In that show I interviewed Dennis Urbaniak, VP U.S. Diabetes. Listen to the podcast: http://bit.ly/PMT098The Sanofi US Diabetes team won the third (2012) Pharmaguy Social Media Pioneer Award.
There are several non-regulatory reasons why pharma companies have not hosted more chats:Pharma companies are concerned about being overwhelmed by adverse events that may pop up in tweets during a chat session that they host and/or moderate.Pharma companies are concerned about "off-label" promotion that may be made by chat participants.Organizing and moderating a chat requires too much effort and is too risky.Once you start a chat, it's very hard to control the message.Consumers don't really want to chat with pharma companies (but physicians would be interested in chats featuring experts discussing the latest research).Despite dire predictions of "PR failure," the chat was a great success and proof that a pharmaceutical company can indeed host meaningful Twitter chats.There were a few attempts by two or three "malcontents" to "hijack" the conversation. These people made the most tweets that included the #rxsave hash tag, but despite their attempts to ask "the tough questions" about off-label promotion of drugs and Seroquel side effects, everyone completely ignored the hijackers and the conversation continued as if these people were not even there.Tony Jewell (@tonyjewell), Senior Director of External Communications at AstraZeneca US, received the 2nd Pharmaguy Social Media Pioneer award for his pioneering use of Twitter.
I first suggested that BI host a #COPDChat back in November, 2010: "It appears to me that a pharma-hosted Twitter chat about a disease condition would be of high interest to consumers and patients [and physicians]. BoehringerIngelhiem, for example, could host a COPD Twitter chat in conjunction with its DRIVE4COPD campaign (eg, #COPDChat).” The #COPDChat is intended for physicians and the news media. It is NOT intended for patients and consumers, although there is no way that the general public can be excluded. Therefore, it seems to me that BI has to assume consumers will be at least "lurking" and may also be posting. The self-regulatory code of the Association of the British Pharmaceutical Industry (ABPI) specifically prohibits Twitter chats even when "intended" for physicians only. The code states:"If a company wanted to promote a medicine via twitter it would have to ensure that if the medicine was prescription only, the audience was restricted to health professionals and that the message, in addition to any link to further information, complied with the Code. In addition companies would also have to ensure that recipients had agreed to receive the information. Given these restrictions and the character limit on twitter, it is highly unlikely that the use of this medium to promote prescription only medicines would meet the requirements of the Code. Using twitter to alert health professionals about the publication of a study on a medicine is likely to be considered promotion of that medicine."BI is a member of the ABPI, hence the reason for its disclaimer that #COPDChat is not intended for a UK audience. It remains to be seen, however, if such disclaimers carry weight with the UK's Prescription Medicines Code of Practice Authority (PMCPA), which oversees ABPI's self-regulatory code.
In closing this section devoted to social media, I would like to emphasize that to implement a strategy for using social media as part of your marketing campaigns, it is important to have a plan. But what are the action items of your implementation plan? This survey asked respondents to indicate how important it is to include the following action items as part of a social media implementation plan:#1: Get everyone - including marketing, regulatory people, corporate communications, C-level execs - on board#2: Become a dialogue company - learn how to listen and respond, not just push messages out#3: Have a sustained vision/goal#4: Train people who will be interacting directly with consumersCreate a social media Tsar position to oversee all the company's SM projects to assure compliance with guidelinesDevelop a moderation strategyDevelop guideposts, internal and external standard operating proceduresMarshall necessary resources - use the best tools availableUnblock corporate access to social media so employees can monitor and use applications such as Facebook while at work
That’s the end of the first part of my presentation. I am open to answering any questions you may have before proceeding to talk about mobile health app challenges.
These are some of the issues relating to mobile health apps developed by pharmaceutical companies that go beyond whether or not they are “mobile medical apps” (MMAs) subject to regulation by the FDA.
Behind every mobile app is a developer – someone hired by pharma to develop apps. In testimony before the U.S. House of Representatives Energy and Commerce Committee Subcommittee on Communications & Technology, several expert witnesses alluded to "garage entrepreneurs" as the driving force behind the "trajectory of innovation" in the development of mobile health apps. They worry that such "small" enterprises do not have the money or knowledge to deal with FDA regulation, especially when it is uncertain which mobile health apps the FDA will or will not deem to be medical devices subject to regulation!
FDA is attempting to ally fears about which types of health apps they may decide to regulate as MMAs. The top of FDA’s “Scope of Oversight” pyramid includes “mobile medical apps” (MMAs) that are traditional medical devices or a part or an extension of a traditional medical device. These are clearly within the scope of FDA’s oversight. The middle section includes patient self-management apps and simple tracking or trending apps not intended for treating/adjusting medication. This is the area, as defined by FDA's Center for Devices and Radiological Health , for enforcement discretion.The bottom section are devices that are not deemed “mobile medical apps” and, as such, have no regulatory requirements.FDA has reserved the term "Mobile Medical App" (MMA) to mean a medical app that meets its medical "device" definition. When talking about mobile apps that clearly are NOT medical devices, I will use the phrase “Mobile Health Apps.”FDA is does NOT consider the following types of apps to be mobile medical apps for purposes of the guidance:"Mobile apps that are solely used to log, record, track, evaluate, or make decisions or suggestions related to developing or maintaining general health and wellness. Such decisions, suggestions, or recommendations are not intended for curing, treating, seeking treatment for mitigating, or diagnosing a specific disease, disorder, patient state, or any specific, identifiable health condition. Examples of these apps include dietary tracking logs, appointment reminders, dietary suggestions based on a calorie counter, posture suggestions, exercise suggestions, or similar decision tools that generally relate to a healthy lifestyle and wellness."
At a March 20, 2013, U.S. House Energy and Commerce Subcommittee on Communications and Technology hearing, Bradley Merrill Thompson, General Counsel to the mHealth Regulatory Coalition, cited a urine analysis smartphone app that was clearly a medical device subject to FDA regulation. He didn’t name the app, but it surely was the uChek Urine Analyzer app.At first, the app’s disclaimer declared that the app was NOT a medical device. "If only it were that simple," said Thompson.Company received “It Has Come to Our Attention” letter from the FDA requesting a “clearance number.The currently-available version of uChek declares that it is a medical device: "The uChek system consisting of the uChek color mat, the Cuboid together with the uChek mobile application is a medical device that simplifies urine analysis."
Many pharmaceutical marketers are developing mobile Apps for consumers and physicians that may or may not be considered MMAs by the FDA. An example is Janssen's "Psoriasis" app for the iPhone and iPad.The physician version -- which any non-physician can easily access -- includes a "PASI calculator." PASI stands for "Psoriasis Area and Severity Index," which is a tool for the measurement of severity of psoriasis. The equation above comes from Wikipedia. Is this how the Janssen app calculates PASI? We don’t know because the app does not indicate the source of the PASI calculation.Is this app a medical device that needs to be approved by the FDA? I think that's a valid question to ask since the App encourages physicians to use it while examining patients to help make a diagnosis.
When I wrote the Pharma Marketing News article "Some Unregulated Physician Smartphone Apps May Be Buggy" back in January 2012, I reported that Pfizer "recalled" its Rheumatology Calculator app because of "a bug in the app ... gives wrong results.”Considering that the "recalled" Pfizer app was the most downloaded app tracked by POCKET.MD at the time, there must be many many users (physicians) out there who still have the app on their phones. At the time, I asked "Did Pfizer send these physicians a 'Dear Doctor' letter informing them of the problem and advising them to remove the app from their phones?" My best guesstimate answer at was: "Probably not.”It turns out, however, that Pfizer UK DID send out a "Dear Doctor" letter in October 2011, warning doctors that:“the Apple iPhone application gives on average a 15-20% higher score for DAS28-ESR compared to a score calculated using the published DAS28-ESR formula (with higher or lower incorrect scores in certain cases). It gives on average a 10-15% lower score for DAS28-CRP compared to a score calculated using the published DAS28-CRP formula2. Incorrect values are also obtained for the ASDAS-CRP score (scores are on average 15-25% lower) and for the PASI score (scores are up to 50% lower). There may also be minor errors in the Framingham scores.”
The more I dig into FDA regulation of mobile health/medical apps, the more I worry that many pharma health apps aimed at consumers may be in FDA's crosshairs.At first, I thought that PhRMA and other industry spokespeople were engaging in a bit of fear mongering when they suggested that the FDA “will soon require apps such as medication prescription renewal reminders and blood glucose level tracking functions to be regulated as medical devices.” Then I interviewed Bradley Merrill Thompson, General Counsel to the mHealth Regulatory Coalition, who mentioned ANOTHER FDA mobile guidance that the drug industry should be concerned about: new guidelines regarding FDA's regulation of clinical decision support (CDS) software.What is CDS? Here's FDA's definition:Uses an individual’s information from various sources (electronically or manually entered) Converts this information into new information that is intended to support a clinical decision Could be a mobile application, web-based service or desk top application#2 could apply to the use of algorithms or formulas such as the Janssen's PASI calculator and other pharma apps.Examples of CDS include mobile apps that remind users to take their medication; e.g. apps that give “reminders for tests, consults or medications.”FDA says its regulation of CDS apps depends on the clinical impact of medical decisions made on the basis of such apps (see chart).
I ran a survey of readers to get their opinions on these issues. This survey asked if respondents agreed or disagreed with the following statements:Apps must include full disclosure regarding the company that has created the app or the sponsoring pharma company. This includes contact information. BRANDED apps MUST include ISI (important safety information) up front in an easily accessible manner (e.g., on start-up screen).Apps that are BRANDED (i.e., mention drug brand names) must be available ONLY from the appropriate U.S. app site (e.g., Apple App Store) even if all the FDA-required ISI (important safety information) is included.Apps intended to be used by healthcare professionals in the U.S. must be HIPAA compliant.If an app collects personal information, it should include a privacy policy that explains how such data is protected (security), who owns the data, how users can access the data, where data is stored (on device or on remote web site) and instructions for opting out of data collection.The pharmaceutical industry has to police itself with regard to development of all health apps regardless of what regulations FDA may impose.The app should include appropriate disclaimers and terms of use that the user MUST agree to before the app will run.All health/medical apps should be certified by third parties such as Happtique.If an app relies on algorithms or formulas, it must be validated through rigorous testing and documentation to ensure it works properly (i.e.,. calculations are correct).
Other survey results suggest that the industry needs to regulate itself to put itself in the best possible position to limit overzealous FDA regulation of health apps.You can the survey and give YOUR opinions here: http://bit.ly/MobileBPsurvey
At the moment, the drug industry is vigorously opposing FDA regulations, suggesting that the FDA is casting too "wide a net" over MMAs. PhRMAopenly expressed fears that overzealous FDA regulations will quash the development of innovative mobile health apps Another way for the pharmaceutical industry to prevent “overzealous” FDA regulations is by differentiating itself from the "wild west" breed of mobile health app developers. The industry should pro-actively issue “Guidelines for Mobile Health Apps Developed by the Pharmaceutical Industry” in much the same manner as it developed other self-regulatory guidelines such as PhRMA's “Code on Interactions With Healthcare Professionals” and International Federation of Pharmaceutical Manufacturers Association's Code of Conduct.These are a few of my personal views regarding issues that voluntary guidelines should address.